kth.sePublications KTH
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The impact of cytotoxic drug type and drug-to-affibody ratio on biodistribution of HER2-targeting affibodydrug conjugates using radiolabeling
Uppsala Univ, Uppsala, Sweden..
Uppsala Univ, Uppsala, Sweden..
KTH.
Uppsala Univ, Uppsala, Sweden..
Show others and affiliations
2024 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 51, p. S315-S315Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Springer Nature , 2024. Vol. 51, p. S315-S315
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:kth:diva-359482ISI: 001332779401254OAI: oai:DiVA.org:kth-359482DiVA, id: diva2:1934887
Conference
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), October 19-23, 2024, Hamburg, Germany
Note

QC 20250205

Available from: 2025-02-05 Created: 2025-02-05 Last updated: 2025-02-05Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Gräslund, Torbjörn

Search in DiVA

By author/editor
Li, R.Gräslund, Torbjörn
By organisation
KTHProtein Technology
In the same journal
European Journal of Nuclear Medicine and Molecular Imaging
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 80 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf